US · MXCT · BIOTECHNOLOGY
MaxCyte, Inc. (MXCT) intrinsic value and stock valuation
$1.37as of 2026-11-21 · Mkt cap 126.4M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
MaxCyte, Inc. DCF and intrinsic value
InvestorsCraft values MXCT with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from MXCT’s statements →
MaxCyte, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $33M | $38.6M | $41.3M | $44.3M | $33.9M |
| Operating income | -$-45.28M | -$-51.2M | -$-48.3M | -$-27.36M | -$-18.19M |
| Net income | -$-44.63M | -$-41.05M | -$-37.92M | -$-23.57M | -$-19.08M |
| EPSd | -$-419.34K | -$-391.51K | -$-367.19K | -$-231.76K | -$-210.55K |
| Operating cash flow | -$-34.41M | -$-27.61M | -$-21.69M | -$-14.78M | -$-10.68M |
| Capital expenditure | -$-1.77M | -$-1.65M | -$-3.7M | -$-18.48M | -$-3.83M |
| Free cash flow | -$-36.18M | -$-29.26M | -$-25.39M | -$-33.26M | -$-14.51M |
| Total assets | $202.5M | $239.5M | $268.3M | $286.7M | $284.1M |
| Total debt | $17.9M | $18M | $18.7M | $16.1M | $5.68M |
| Net debt | -$-2.12M | -$-9.85M | -$-27.76M | $5.03M | -$-42.1M |
| Total equity | $171.5M | $206.3M | $232.2M | $254M | $262.9M |
| Cash and short-term investments | $103M | $154.5M | $168.3M | $227.3M | $255M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $33M | $38.6M | $41.3M | $44.3M | $33.9M |
| Cost of revenue | $6.22M | $7.1M | $4.74M | $5.1M | $3.65M |
| Gross profit | $26.8M | $31.5M | $36.6M | $39.2M | $30.3M |
| Research and development expenses | $20.8M | $22.2M | $23.8M | $19.5M | $15.4M |
| Selling, general and administrative expenses | $47M | $56.4M | $57M | $44.5M | $31.7M |
| Other expenses | $4.23M | $4.14M | $3.98M | $2.53M | $1.35M |
| Operating expenses | $72.1M | $82.7M | $84.8M | $66.5M | $48.4M |
| Cost and expenses | $78.3M | $89.8M | $89.6M | $71.6M | $52.1M |
| Interest income | $7.27M | $10.1M | $10.4M | $3.92M | $150K |
| Interest expense | $0.00 | $0.00 | $0.00 | $130K | $1.04M |
| Depreciation and amortization | $5.14M | $4.79M | $4.17M | $2.7M | $1.42M |
| Ebitda | -$-39.49M | -$-36.27M | -$-33.75M | -$-20.75M | -$-16.61M |
| Operating income | -$-45.28M | -$-51.2M | -$-48.3M | -$-27.36M | -$-18.19M |
| Total other income/expenses, net | $660K | $10.1M | $10.4M | $3.79M | -$-890K |
| Income before tax | -$-44.63M | -$-41.05M | -$-37.92M | -$-23.57M | -$-19.08M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-44.63M | -$-41.05M | -$-37.92M | -$-23.57M | -$-19.08M |
| Weighted average shares outstanding | $106.4M | $104.9M | $103.3M | $101.7M | $90.6M |
| Weighted average diluted shares outstanding | $106.4M | $104.9M | $103.3M | $101.7M | $90.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $103M | $154.5M | $168.3M | $227.3M | $255M |
| Net receivables | $3.5M | $4.68M | $5.78M | $11.2M | $6.88M |
| Inventory | $7.55M | $8.91M | $12.2M | $8.58M | $5.2M |
| Total current assets | $118.4M | $171.7M | $190.2M | $252.3M | $270.4M |
| Property, plant and equipment, net | $28.5M | $30.5M | $34.8M | $33.6M | $13.4M |
| Goodwill and intangible assets | $650K | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $52.6M | $35.8M | $42.9M | $0.00 | $0.00 |
| Total non-current assets | $84.1M | $67.8M | $78.1M | $34.4M | $13.7M |
| Total assets | $202.5M | $239.5M | $268.3M | $286.7M | $284.1M |
| Accounts payable | $1.4M | $1.36M | $740K | $290K | $1.82M |
| Short-term debt | $1.46M | $860K | $770K | $160K | $530K |
| Deferred revenue | $3.6M | $5.25M | $5.07M | $0.00 | $6.75M |
| Total current liabilities | $14.3M | $15.8M | $17.9M | $15.4M | $15.6M |
| Long-term debt | $16.5M | $17.2M | $18M | $15.9M | $5.15M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $16.8M | $17.4M | $18.3M | $17.3M | $5.61M |
| Capital lease obligations | $16.5M | $17.2M | $18.7M | $16.1M | $5.68M |
| Total liabilities | $31M | $33.2M | $36.1M | $32.7M | $21.2M |
| Common stock | $1.07M | $1.06M | $1.04M | $1.02M | $1.01M |
| Retained earnings | -$-261.48M | -$-216.85M | -$-175.8M | -$-137.88M | -$-114.3M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | -$0.00 | $0.00 |
| Total equity | $171.5M | $206.3M | $232.2M | $254M | $262.9M |
| Total investments | $135.6M | $162.4M | $164.7M | $216.3M | $207.3M |
| Total debt | $17.9M | $18M | $18.7M | $16.1M | $5.68M |
| Net debt | -$-2.12M | -$-9.85M | -$-27.76M | $5.03M | -$-42.1M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-44.63M | -$-41.05M | -$-37.92M | -$-23.57M | -$-19.08M |
| Depreciation and amortization | $5.14M | $4.32M | $4.57M | $2.7M | $1.42M |
| Stock-based compensation | $9.21M | $0.00 | $14M | $0.00 | $7.96M |
| Change in working capital | -$-6.12M | -$-750K | $3.82M | -$-3.21M | -$-1.64M |
| Accounts receivable | $1.15M | $1.23M | $7.14M | -$-6.69M | -$-1.71M |
| Inventory | $570K | $1.36M | -$-4.53M | -$-3.49M | -$-1.41M |
| Accounts payable | -$-3.72M | -$-1.88M | $3.25M | -$-150K | $2.09M |
| Net cash provided by operating activities | -$-34.41M | -$-27.61M | -$-21.69M | -$-14.78M | -$-10.68M |
| Investments in property, plant and equipment | -$-1.77M | -$-1.65M | -$-3.7M | -$-18.48M | -$-3.83M |
| Acquisitions, net | -$-1.77M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $25.9M | $6.93M | $55M | -$-24.82M | -$-195.01M |
| Common stock issued | $660K | $2.06M | $270K | $2.89M | $236.1M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $660K | $2.06M | $2.14M | $2.89M | $234.7M |
| Net change in cash | -$-7.82M | -$-18.62M | $35.4M | -$-36.72M | $29M |
| Cash at end of period | $20.1M | $27.9M | $46.5M | $11.1M | $47.8M |
| Operating cash flow | -$-34.41M | -$-27.61M | -$-21.69M | -$-14.78M | -$-10.68M |
| Capital expenditure | -$-1.77M | -$-1.65M | -$-3.7M | -$-18.48M | -$-3.83M |
| Free cash flow | -$-36.18M | -$-29.26M | -$-25.39M | -$-33.26M | -$-14.51M |
Line items
Line items
Line items
About MaxCyte, Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
- CEO
- Maher Masoud
- Employees
- 91
- Beta
- 1.49
Explore
Frequently asked questions
What is the intrinsic value of MaxCyte, Inc. (MXCT)?
MaxCyte, Inc. (MXCT) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is MXCT undervalued?
MXCT trades at a price of $1.37 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.